The majority of hepatitis C virus (HCV) and human immunodeficiency virus (HIV) coinfection
occurs among persons who inject drugs. Rapid improvements in responses to HCV therapy …

Background Despite the key role that people who inject drugs (PWID) play in the hepatitis C
virus (HCV) epidemic, HCV treatment rates among this population have been historically …

We characterized hepatitis C virus (HCV) treatment knowledge, experience and barriers in a
cohort of community-based injection drug users (IDUs) in Baltimore, MD. In 2005, a …

BACKGROUND: Illicit drug users account for the majority of cases of HCV infection in the
developed world, but few have received treatment. METHODS: We evaluated barriers to …

Background As highly effective hepatitis C virus (HCV) therapies emerge, data are needed
to inform the development of interventions to improve HCV treatment rates. We used …

Background High hepatitis C virus (HCV) rates have been reported in young people who
inject drugs (PWID). We evaluated the clinical benefit and cost-effectiveness of testing …

Objectives We evaluated assessment and treatment for hepatitis C virus (HCV) among illicit
drug users accepting referral to a weekly HCV peer-support group at a multidisciplinary …

Despite a high prevalence of hepatitis C virus (HCV) infection, the vast majority of persons
who inject drugs (PWID) have not engaged in HCV care due to a large number of obstacles …

Objective: To evaluate predictors and trends of referral for hepatitis C virus (HCV) care, clinic
attendance and treatment in an urban HIV clinic. Design and methods: A retrospective …

Emerging data indicate that all‐oral antiviral treatments for chronic hepatitis C virus (HCV)
will become a reality in the near future. In replacing interferon‐based therapies, all‐oral …